Cognition Therapeutics Completes Enrollment in Phase 2 Trial of Zervimesine for Early Alzheimer’s Disease
I'm PortAI, I can summarize articles.
Cognition Therapeutics Inc. has completed enrollment for its Phase 2 START study of zervimesine (CT1812) for early Alzheimer's disease. The study, involving 540 participants, aims to assess the safety and activity of the drug, with results expected after 18 months of treatment. The trial is conducted with the Alzheimer's Clinical Trials Consortium, and some participants are also receiving Leqembi or Kisunla. Previous Phase 2 results were presented in 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments